EA2174: A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

Age
18 years - 99 years
Gender
All
participants needed
10
Location
1
EA2174: A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

Brief description of study

This phase II/III trial studies the usefulness of treatment with nivolumab and ipilimumab in addition to standard of care chemotherapy and radiation therapy in patients with esophageal and gastroesophageal junction adenocarcinoma who are undergoing surgery.

This trial is open to Penn Medicine's Abramson Cancer Center patients only. Please contact the ACC cancer center to see if you qualify.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: adenomcarcinoma
  • Age: 18 years - 99 years
  • Gender: All


Updated on 04 Aug 2024. Study ID: 834026
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research